540
Views
12
CrossRef citations to date
0
Altmetric
Review

Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

Pages 323-332 | Received 01 Feb 2018, Accepted 19 Mar 2018, Published online: 02 Apr 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Christian Cheng, Nicholas Brownstone & John Koo. (2022) Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis. Journal of Dermatological Treatment 33:3, pages 1319-1323.
Read now
Robert H. Farber, Angel Angelov, Kristine Kim, Tara Carmack, Dao Thai-Cuarto & Eiry Roberts. (2021) Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Review of Neurotherapeutics 21:4, pages 393-404.
Read now
Laszlo Szpisjak, Andras Salamon, Denes Zadori, Peter Klivenyi & Laszlo Vecsei. (2020) Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?. Expert Opinion on Pharmacotherapy 21:1, pages 1-4.
Read now
Stanley N Caroff. (2019) Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatric Disease and Treatment 15, pages 785-794.
Read now

Articles from other publishers (8)

D.V. Zakharov, Iu.V. Buriak & V.A. Mihailov. (2022) Tardive neuroleptic-induced dyskinesias. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:1, pages 31.
Crossref
Jean-Pierre Lindenmayer, Cherian Verghese, Stephen R. Marder, Joshua Burke, Roland Jimenez, Scott Siegert, Grace S. Liang & Christopher F. O’Brien. (2020) A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectrums 26:4, pages 345-353.
Crossref
Stanley N. Caroff. (2020) Recent Advances in the Pharmacology of Tardive Dyskinesia. Clinical Psychopharmacology and Neuroscience 18:4, pages 493-506.
Crossref
Stanley N. Caroff. (2020) Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors. Clinical Psychopharmacology and Neuroscience 18:2, pages 322-326.
Crossref
Ece YAZLA & Çiçek HOCAOĞLU. (2019) Tardif Diskinezi için Güncel Tanı ve Tedavi YaklaşımlarıThe Diagnosis And Current Treatment Approaches For The Tardive Dyskinesia. Balıkesir Medical Journal 3:2, pages 73-84.
Crossref
Kristen M. Ward & Leslie Citrome. (2018) Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. Neurology and Therapy 7:2, pages 233-248.
Crossref
Leslie Citrome. (2018) Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. Evidence Based Mental Health 21:3, pages e12-e12.
Crossref
Stephen M. Stahl. (2018) Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?. CNS Spectrums 23:4, pages 239-247.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.